Clinical trials: Depressive Symptoms
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01372150
- Testing
- desvenlafaxine succinate sustained release, fluoxetine
- Where
- 43 sites in United States, Mexico
- Volunteers
- 340 people
- Sponsor
- Pfizer
Depressive Disorder, Major
Study of Rapastinel as Monotherapy in Patients With MDD
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
- Trial name
- NCT03560518
- Testing
- Rapastinel
- Where
- 40 sites in United States
- Volunteers
- 439 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE (NCT07594483)
- Testing
- Motif XCS System
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Motif Neurotech, Inc.
Depression
Effect of a Single Virtual Reality Exposure on Depressive Symptoms (Veovita-VR)
The trial aims to evaluate the effectiveness of a novel virtual reality (VR) intervention (Veovita-VR) designed to expose people with at least moderate depressive symptoms to positive emotional stimuli and positive behavioral…
- Trial name
- NCT05529797
- Testing
- Veovita-VR
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- Gaia AG
Depression, Depressive Disorder
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
- Trial name
- NCT02452892
- Testing
- LFMS
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Tal Medical, Inc.
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
- Trial name
- NCT01640080
- Testing
- Esketamine
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode.
- Trial name
- NCT01684163
- Testing
- GLYX-13 5 mg/kg, GLYX-13 10 mg/kg
- Where
- 26 sites in United States
- Volunteers
- 369 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Anhedonia, Major Depressive Disorder (MDD)
Efficacy of kTMP, a Novel Non-invasive Brain Stimulation Method, for the Treatment of Anhedonia
The goal of this proposal is to provide a first assessment of the efficacy of our innovative non-invasive brain stimulation system, kTMP, in the treatment of anhedonia in MDD.
- Trial name
- kTMP Anhedonia (NCT07032428)
- Testing
- A new non-invasive brain stimulation tool
- Volunteers
- 104 people
- Sponsor
- Magnetic Tides
Depression
Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects
The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in…
- Trial name
- NCT01046630
- Testing
- AZD6765, Ketamine
- Where
- 2 sites in United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder, Dementia
Vortioxetine in Patients With Depression and Early Dementia
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia
- Trial name
- MEMORY (NCT04294654)
- Testing
- Vortioxetine
- Where
- 24 sites in Estonia, France and 4 more
- Volunteers
- 82 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06963021
- Testing
- NBI-1065845
- Where
- 35 sites in United States, Belgium and 5 more
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06423781
- Testing
- BHV-7000
- Where
- 66 sites in United States
- Volunteers
- 233 people
- Sponsor
- Biohaven Therapeutics Ltd.
Major Depressive Disorder
Study of Technology-assisted Treatment of Adolescent Depression
The purpose of this study is to evaluate a computer-guided, telephone-based therapy for adolescent depression, delivered in a pediatric primary setting in the community.
- Trial name
- iTAD (NCT01582581)
- Testing
- Telephonic CBT, Wait List Control
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- iHope Network, Inc.
Mental Disorders
Combination Of PAXIL Tablet And Benzodiazepines
This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive episodes who have received…
- Trial name
- NCT00259883
- Testing
- paroxetine
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
- Trial name
- MAGELLAN (NCT01428661)
- Testing
- tasimelteon
- Where
- 40 sites in United States
- Volunteers
- 507 people
- Sponsor
- Vanda Pharmaceuticals
Major Depressive Disorder
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone.
- Trial name
- NCT01469377
- Testing
- Cariprazine
- Where
- 72 sites in United States, Estonia and 4 more
- Volunteers
- 819 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel.
- Trial name
- GATE-251 (NCT07115329)
- Testing
- Zelquistinel
- Where
- 32 sites in United States
- Volunteers
- 164 people
- Sponsor
- Syndeio Biosciences, Inc
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111539
- Testing
- Escitalopram, Aripiprazole, Blinded capsule
- Where
- 62 sites in United States, Estonia and 7 more
- Volunteers
- 211 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.